The advent of biological disease-modifying anti-rheumatic drugs (bDMARDs), including anti-tumour necrosis factor (TNF) therapy, has revolutionised the treatment of RA and made remission a realistic goal for many people with RA. Here, TNF is linked to rheumatoid arthritis.